Advertisement

Antidepressant Medication Use, Weight Gain and Risk of Type 2 Diabetes Mellitus: A Population-based Study

  1. Mika Kivimäki, PhD (m.kivimaki{at}ucl.ac.uk)1,2,
  2. Mark Hamer, PhD1,
  3. G. David Batty, PhD1,3,
  4. John R. Geddes, MD, FRCPsych4,
  5. Adam G. Tabak, MD, PhD1,5,
  6. Jaana Pentti, MSc6,
  7. Marianna Virtanen, PhD6 and
  8. Jussi Vahtera, MD, PhD6,7
  1. From 1 Department of Epidemiology and Public Health, University College London, UK
  2. 2 Department of Behavioral Sciences, University of Helsinki, Finland
  3. 3 MRC Social & Public Health Sciences Unit, University of Glasgow, UK
  4. 4 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
  5. 5 1st Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary
  6. 6 Finnish Institute of Occupational Health, Helsinki, Finland
  7. 7 University of Turku, Turku University Hospital, Turku, Finland

Abstract

Objective— To examine antidepressant medication use as a risk factor for type 2 diabetes and weight gain.

Research design and methods— A series of nested studies within a prospective cohort of 151,347 working-aged men and women including 9197 participants with continuing antidepressant medication, 224 with severe depression, and 851 with incident type 2 diabetes mellitus during a mean follow-up of 4.8 years, as indicated by national health and prescription registers (the Public Sector study, Finland 1995-2005).

Results— In the first analysis, the cases were individuals with incident type 2 diabetes compared with matched diabetes-free controls. Antidepressant use of ≥200 defined daily doses was associated with a doubling of diabetes risk in both participants with no indication of severe depression (odds ratio 1.93, 95% CI 1.48-2.51) and participants with severe depression (odds ratio 2.65 95% CI 1.31-5.39). In the further analyses, exposed group was antidepressant users and reference group non-users matched for depression-related characteristics. The 5-year absolute risk of diabetes was 1.1% for non-users, 1.7% for individuals treated with 200-399 defined daily doses a year, and 2.3% for those with ≥400 defined daily doses (ptrend<0.0001). An average self-reported weight gain, based on repeated surveys, was 1.4 kg (2.5%) among non-users and 2.5 kg (4.3%) among users of ≥200 defined daily doses (ptrend<0.0001). Separate analyses for tricyclic antidepressants and selective-serotonin-re-uptake inhibitors replicated these findings.

Conclusions— In these data, continuing use of antidepressant medication was associated with an increased relative risk of type 2 diabetes, although the elevation in absolute risk was modest.

Footnotes

    • Received June 21, 2010.
    • Accepted August 27, 2010.

    This Article

    1. Diabetes Care September 7, 2010
    1. Online Appendix
    2. All Versions of this Article:
      1. dc10-1187v1
      2. 33/12/2611 most recent
    Advertisement